-

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026.

The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PST/10:30 a.m. ET.

The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
Release Versions

Contacts

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans...

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma...
Back to Newsroom